Drug Repurposing in Oncology : A Systematic Review of Randomized Controlled Clinical Trials
Quality pharmacological treatment can improve survival in many types of cancer. Drug repurposing offers advantages in comparison with traditional drug development procedures, reducing time and risk. This systematic review identified the most recent randomized controlled clinical trials that focus on drug repurposing in oncology. We found that only a few clinical trials were placebo-controlled or standard-of-care-alone-controlled. Metformin has been studied for potential use in various types of cancer, including prostate, lung, and pancreatic cancer. Other studies assessed the possible use of the antiparasitic agent mebendazole in colorectal cancer and of propranolol in multiple myeloma or, when combined with etodolac, in breast cancer. We were able to identify trials that study the potential use of known antineoplastics in other non-oncological conditions, such as imatinib for severe coronavirus disease in 2019 or a study protocol aiming to assess the possible repurposing of leuprolide for Alzheimer's disease. Major limitations of these clinical trials were the small sample size, the high clinical heterogeneity of the participants regarding the stage of the neoplastic disease, and the lack of accounting for multimorbidity and other baseline clinical characteristics. Drug repurposing possibilities in oncology must be carefully examined with well-designed trials, considering factors that could influence prognosis.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Cancers - 15(2023), 11 vom: 30. Mai |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ioakeim-Skoufa, Ignatios [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antineoplastic agents |
|---|
| Anmerkungen: |
Date Revised 12.06.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.3390/cancers15112972 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357986911 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357986911 | ||
| 003 | DE-627 | ||
| 005 | 20231226073758.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/cancers15112972 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1193.xml |
| 035 | |a (DE-627)NLM357986911 | ||
| 035 | |a (NLM)37296934 | ||
| 035 | |a (PII)2972 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ioakeim-Skoufa, Ignatios |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug Repurposing in Oncology |b A Systematic Review of Randomized Controlled Clinical Trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.06.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a Quality pharmacological treatment can improve survival in many types of cancer. Drug repurposing offers advantages in comparison with traditional drug development procedures, reducing time and risk. This systematic review identified the most recent randomized controlled clinical trials that focus on drug repurposing in oncology. We found that only a few clinical trials were placebo-controlled or standard-of-care-alone-controlled. Metformin has been studied for potential use in various types of cancer, including prostate, lung, and pancreatic cancer. Other studies assessed the possible use of the antiparasitic agent mebendazole in colorectal cancer and of propranolol in multiple myeloma or, when combined with etodolac, in breast cancer. We were able to identify trials that study the potential use of known antineoplastics in other non-oncological conditions, such as imatinib for severe coronavirus disease in 2019 or a study protocol aiming to assess the possible repurposing of leuprolide for Alzheimer's disease. Major limitations of these clinical trials were the small sample size, the high clinical heterogeneity of the participants regarding the stage of the neoplastic disease, and the lack of accounting for multimorbidity and other baseline clinical characteristics. Drug repurposing possibilities in oncology must be carefully examined with well-designed trials, considering factors that could influence prognosis | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a antineoplastic agents | |
| 650 | 4 | |a drug repositioning | |
| 650 | 4 | |a etodolac | |
| 650 | 4 | |a imatinib | |
| 650 | 4 | |a leuprolide | |
| 650 | 4 | |a mebendazole | |
| 650 | 4 | |a medical oncology | |
| 650 | 4 | |a metformin | |
| 650 | 4 | |a multimorbidity | |
| 650 | 4 | |a propranolol | |
| 700 | 1 | |a Tobajas-Ramos, Natalia |e verfasserin |4 aut | |
| 700 | 1 | |a Menditto, Enrica |e verfasserin |4 aut | |
| 700 | 1 | |a Aza-Pascual-Salcedo, Mercedes |e verfasserin |4 aut | |
| 700 | 1 | |a Gimeno-Miguel, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Orlando, Valentina |e verfasserin |4 aut | |
| 700 | 1 | |a González-Rubio, Francisca |e verfasserin |4 aut | |
| 700 | 1 | |a Fanlo-Villacampa, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Lasala-Aza, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Ostasz, Ewelina |e verfasserin |4 aut | |
| 700 | 1 | |a Vicente-Romero, Jorge |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancers |d 2009 |g 15(2023), 11 vom: 30. Mai |w (DE-627)NLM198667213 |x 2072-6694 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2023 |g number:11 |g day:30 |g month:05 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/cancers15112972 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2023 |e 11 |b 30 |c 05 | ||